Quantum Genomics is developing a new therapeutic approach based on Brain Aminopeptidase A inhibition (BAPAI) , which result from more than twenty years of academic research in the laboratories of the Collège de France, INSERM and CNRS.
The research conducted by the team of Professor Bernard-Pierre Roques (INSERM U1022 / CNRS Unit/ Université Paris Descartes) and the team of Dr. Catherine Llorens-Cortes (INSERM U1050 / Collège de France) characterized the role of the brain renin-angiotensin system (RAS) and more particularly that of aminopeptidase A (APA) in the control of certain cardiovascular functions including blood pressure. This research work also resulted in the synthesis and characterization of original non-peptide molecules that selectively inhibit APA such as the QGC001 product (originally named RB150).
Quantum Genomics holds an exclusive and global license for the exploitation of several patents and know-how held by INSERM and CNRS around the BAPAI technology. These patents also protect the therapeutic use in humans and animals of aminopeptidase A inhibitors, amongst which are the QGC001 and QGC006 products.
Professor Emeritus at the Collège de France Honorary administrator of the Collège de France Member of the Academy of Sciences Member of the Academy of Medicine Member of the American Academy of Arts and Sciences
PHD in Neurobiology Director of the Neuropeptides centraux et régulation hydrique et Cardiovasculaire (Central Neuropeptides and cardio-vascular hydro-regulation) research team- Collège de France CIRB-CNRS UMR U1050 7241/INSERM
Professor Emeritus at the University Paris Descartes br> Member of the Academy of Sciences br> Member of the European Academy of Sciences br> Member of the American college of Neuro-psychopharmacology
Doctor in Chemistry (PhD) br> Formerly Professor Pierre and Marie Curie University